Related references
Note: Only part of the references are listed.The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers
P. A. Smink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers
P. A. Smink et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2014)
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
Hiddo J. Lambers Heerspink et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2014)
Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis
Gianluigi Savarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Phase II and Phase III attrition rates 2011-2012
John Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Y. Miao et al.
DIABETOLOGIA (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Paul M. Ridker et al.
LANCET (2009)
Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A Randomized controlled study of benazepril and losartan in chronic renal insufficiency
Fan Fan Hou et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Wouter B. A. Eijkelkamp et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
D de Zeeuw et al.
CIRCULATION (2004)
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
TH Jafar et al.
KIDNEY INTERNATIONAL (2001)
Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
MA Albert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
